Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed stage III ovarian epithelial cancer or gastrointestinal cancer with peritoneal involvement
• Patients with ovarian cancer must have completed first induction treatment with a platinum based regimen (carboplatin and/or cisplatin) and be in clinical complete response at time of assessment for study
• No ovarian cancer of low malignant potential
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• Greater than 2 months
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin less than 1.5 mg/dL
• SGOT less than 3 times upper limit of normal
• Renal:
• Creatinine clearance at least 40 mL/min
• Other:
• No underlying medical or psychiatric condition that precludes informed consent
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• See Disease Characteristics
• At least 3 weeks since prior chemotherapy and recovered
• Endocrine therapy:
• Not specified
• Radiotherapy:
• Not specified
• Surgery:
• Laparoscopy or laparotomy required within 8 weeks of study to assess residual disease